Treatment of Secondary Osteonecrosis of the Knee With Local Debridement and Osteoprogenitor Cell Grafting

Goodman, Stuart B.; Hwang, Katherine

doi:10.1016/j.arth.2015.05.013

Cited by 17 publications

(15 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to increase the number of stem cells at the injury site, Hernigou, Poignard, Zilber, and Rouard () transplanted autologous bone marrow into necrotic femoral heads and found better outcomes in patients receiving higher number of progenitors. Goodman and Hwang () found similar results with the same technique treating young individuals with secondary osteonecrosis of the knee. However, stem cell functionality decreases with age, thereby increasing the need for high multipotent cell number at the injury site (Quarto, Thomas, & Liang, ; Shigeno & Ashton, ).…”

Section: Discussionmentioning

confidence: 74%

Serum albumin‐coated bone allograft (BoneAlbumin) results in faster bone formation and mechanically stronger bone in aging rats

Horváthy

Schandl

Schwarz

et al. 2019

J Tissue Eng Regen Med

View full text Add to dashboard Cite

Serum albumin‐coated bone allografts (BoneAlbumin) have successfully supported bone regeneration in various experimental models by activating endogenous progenitors. However, the effect of tissue aging, linked to declining stem cell function, has yet to be explicitly examined within the context of BoneAlbumin's regenerative capacity. Stem cell function was tested with an in vitro attachment assay, which showed that albumin coating increases stem cell attachment on demineralized bone surfaces in an aging cell population. Bone regeneration was investigated in vivo by creating critical size bone defects on the parietal bones of aging female rats. Demineralized bone matrices with and without serum albumin coating were used to fill the defects. Bone regeneration was determined by measuring the density and the size of the remaining bone defect with computed tomography (CT). Microcomputed tomography (MicroCT) and mechanical testing were performed on the parietal bone explants. In vivo CT and ex vivo microCT measurements showed better regeneration with albumin‐coated grafts. Additionally, the albumin‐coated group showed a twofold increase in peak fracture force compared with uncoated allografts. In the present study, serum albumin‐coated demineralized bone matrices successfully supported faster and functionally superior bone regeneration in aging rats. Because stem cell function, a key contributor of bone remodelling, decreases with age and serum albumin is an effective activator of endogenous progenitor cells, this method could be an effective and safe adjuvant in bone regeneration of aging adult and osteo‐compromised populations.

show abstract

Section: Discussionmentioning

confidence: 74%

Serum albumin‐coated bone allograft (BoneAlbumin) results in faster bone formation and mechanically stronger bone in aging rats

Horváthy

Schandl

Schwarz

et al. 2019

J Tissue Eng Regen Med

View full text Add to dashboard Cite

show abstract

“…In some cases, autologous bmMSC were combined with beta-tricalcium phosphate ceramic composites (53) or mixed with allogeneic MSC before implantation. Recently, good results were shown with harvested osteoprogenitor cells for grafting secondary osteonecrosis of the knee (54). In another study of patients with sickle cell disease, decompression and autologous bone marrow grafting proved effective with a reduced incidence (only 12.5%) of collapse after 5 years of follow-up compared to 87% collapse seen historically.…”

Section: Use Of Msc For Orthopaedic Problemsmentioning

confidence: 99%

Stem Cell Considerations for the Clinician

Hasty

Cho

2016

Physical Medicine and Rehabilitation Clinics of North America

View full text Add to dashboard Cite

Summary While there is ample evidence that beneficial results can be obtained from the use of MSC, several questions regarding their use remain to be answered. A better definition is needed for the mechanism/s by which the MSC are eliciting the positive outcome of their use whether it lies in the paracrine factors that are made by the MSC that affect the innate or adaptive immunity or impact the metabolism of resident cells, or their contribution as precursor cells giving rise to more differentiated reparative cells. If paracrine effects are desirable, commercial sources of allogeneic MSC could provide an easily obtainable, well-characterized reagent for the clinician. In their function as reparative cells, the longevity and fate of allogeneic MSC needs to be further evaluated on longer-term basis. The use of autologous cells has both advantages and its own inherent disadvantages involving additional procedures for collection, preparation and characterization of the MSC. It is apparent that a critical number of MSC are necessary for an optimal outcome for implantation. It remains to be determined if tissues such as adipose tissue provide more MSC than bone marrow and if the capability for differentiation is equivalent. A better understanding is also needed for how individual patient factors such as age, sex, drug regimens and co-morbidities influence the MSC population. For many of these questions, preclinical models will be helpful, but the task of evaluating and implementing these findings for orthopaedic patients falls onto the shoulders of clinical researchers. Evaluation of these questions is a daunting, but such a challenge fits the concept of personalized medicine in today’s medicine.

show abstract

“…Cell‐therapy technology is a potential alternative to overcome some of the limitations of autologous bone grafts . Potential indications for these treatments include repair of traumatic injuries, pseudoarthrosis, osteonecrosis, revision arthroplasty for wear particle‐induced peri‐prosthetic osteolysis, and bone defects of other etiologies …”

Section: Introductionmentioning

confidence: 99%

“…Transplantation of bone marrow concentrate (BMC) is another option for cell‐based therapy . In clinical scenarios, Heringou et al have shown that the efficacy of autologous cell therapy for the treatment of fracture nonunions is dependent on the number and concentration of osteoprogenitor cells injected into the site.…”

Section: Introductionmentioning

confidence: 99%

Osteogenic ability of rat bone marrow concentrate is at least as efficacious as mesenchymal stem cellsin vitro

et al. 2019

Self Cite

View full text Add to dashboard Cite

Cell therapy using bone marrow concentrate (BMC) or purified and expanded mesenchymal stem cells (MSCs) has been shown to have a promising osteogenic capacity. However, few studies have directly compared their relative osteogenic ability. The aim of this study was to compare the osteogenic ability of BMC isolated by density gradient centrifugation with bone marrow‐derived MSCs in vitro using the cells of 3‐month‐old Sprague–Dawley rats. The isolated cells were seeded onto 24‐well plates (1 × 105 cells/well) and cultured in control growth media, osteogenic media with dexamethasone, or media without dexamethasone (which simulated the in vivo tissue environment). Alkaline phosphatase activity at week 2, osteocalcin using quantitative real‐time polymerase chain reaction at week 4, and Alizarin red staining at week 4 were evaluated. In the osteogenic media with dexamethasone, BMC showed equivalent (osteocalcin) or even greater (Alizarin red staining) osteogenic ability compared to MSCs, suggesting that cross‐talk among various cells in the BMC leads to greater osteogenesis. Furthermore, in the osteogenic media without dexamethasone, BMC showed equivalent (osteocalcin) or a trend for greater (Alizarin red staining) bone formation than MSCs alone. Our results suggest that BMC has at least comparable bone regeneration potential to MSCs. © 2019 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 107B:2500–2506, 2019

show abstract

Treatment of Secondary Osteonecrosis of the Knee With Local Debridement and Osteoprogenitor Cell Grafting

Cited by 17 publications

References 38 publications

Serum albumin‐coated bone allograft (BoneAlbumin) results in faster bone formation and mechanically stronger bone in aging rats

Serum albumin‐coated bone allograft (BoneAlbumin) results in faster bone formation and mechanically stronger bone in aging rats

Stem Cell Considerations for the Clinician

Osteogenic ability of rat bone marrow concentrate is at least as efficacious as mesenchymal stem cellsin vitro

Contact Info

Product

Resources

About